Weight Loss Treatment

Mounjaro contains Tirzepatide as an active ingredient, it is a first-in-class medicine that activates both the GLP-1 (Glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, which leads to improved blood sugar control and improved insulin sensitivity.  

Mounjaro has garnered significant attention for its effectiveness in controlling type 2 diabetes and aiding in weight management. Clinical studies have shown remarkable results, with obese and overweight individuals experiencing significant weight reductions of around 20-25% over a year when compared to placebo treatments.

Mounjaro works by increasing insulin secretion & sensitivity. It also suppresses glucagon activity and appetite, which reduces overall food intake. The combination of GIP and GLP-1 also slows gastric emptying, thereby reducing appetite and making you feel fuller for longer.

Mounjaro is administered as a subcutaneous injection (under the skin) ONCE weekly. It is available in 6 different strengths. The initial dose is 2.5mg ONCE weekly, increased by 2.5mg once every 4 weeks if tolerated well. 

Wegovy is a licensed treatment for weight loss and weight maintenance, intended to be used in conjunction with diet and exercise in adults. Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. It helps improve blood glucose control, reduce appetite, and increase satiety.

In clinical trials, participants using Wegovy lost up to 15% body weight. Evidence suggests that using Wegovy in addition to diet and exercise is more effective than diet and exercise alone. 

Your program includes a prescription of Wegovy, weight tracking, and additional help from medical professionals in your weight loss journey. 

If you haven't used any weight loss medication in the past two weeks, you will be prescribed the 0.25mg starting dose.